Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04922853 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer

Study acronym: COPEC
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruitingv4 Show 4 more changesShow less
    • Primary completion date changed from estimate of Dec 1, 2024 to Oct 1, 2024
    • Study completion date: Dec 1, 2026 to Dec 1, 2027
    • Site details revised at 4 of 4 sites
    • Collaborators revised (14)
  2. Enrollment target: 562 to 554v3 Show 4 more changesShow less
    • Study sites: 3 to 4
    • Start date changed from estimate of Jul 26, 2021 to Aug 26, 2021
    • Collaborators: 4 to 14
    • Study title expanded, about 2 words
  3. Start date: Jun 20, 2021 to Jul 26, 2021v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To compare the pathological effect between 2 cycles and 4 cycles of Capox regimen as neoadjuvant chemotherapy for low/ intermediate risk stage II/III rectal cancer.
Trial Details
NCT Number NCT04922853
Lead Sponsor West China Hospital
Collaborators: The Third People's Hospital of Chengdu, Chengdu Fifth People's Hospital, Peking Union Medical College, Peking University Cancer Hospital & Institute, Sun Yat-Sen University Cancer Center, Second Affiliated Hospital, Zhejiang University, School of Medicine, Yunnan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Affiliated Hospital Of Guizhou Medical University, Sichuan Provincial People's Hospital, Nanchong Central Hospital, Dazhou Central Hospital, Leshan People's Hospital, GeneCast Biotechnology Co., Ltd.
Conditions
(from sponsor)		 Rectal Cancer, Neoadjuvant Chemotherapy
Related terms Rectal Neoplasms
Enrollment 554 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov